We found that CDKN2A/B codeletion but not CDKN2A mutation alone correlated with poor survival outcomes, suggesting a key role of both p15 and p16 losses in determining the prognosis of CDKN2A/B co-deleted HNSCC. Here, CDKN2B is linked to head and neck squamous cell carcinoma.